Pembrolizumab-Induced Axial Spondyloarthritis

Abstract

Get full access to this article

View all access options for this article.

References

Angelopoulou

Bogdanos

Dimitroulas

Sakkas

Daoussis

Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int. 2021;41(1):33-42. doi:10.1007/s00296-020-04665-7

Taurog

Chhabra

Colbert

RA.

Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563-2574. doi:10.1056/NEJMra1406182

McDermott

Lee

Ziobro

, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029-1039. doi:10.1200/JCO.20.02365

Rudwaleit

van der Heijde

Landewé

, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31. doi:10.1136/ard.2010.133645

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154